Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD

600.71

-14.07 (-2.29%)

At close: Jun 1, 2026, 4:00 PM EDT

600.01

-0.70 (-0.12%)

After-hours: Jun 1, 2026, 4:12 PM EDT

Regeneron Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	4,423	4,505	4,413	3,954	4,338	8,075
Depreciation & Amortization	540	543.7	482.9	421	341.4	286.2
Stock-Based Compensation	995.4	993.7	982.8	885	725	601.7
Other Adjustments	-1,386	-1,596	-839.5	-571.5	-146.6	34.6
Change in Receivables	-158.5	498.1	-554	-338.8	707.8	-1,927
Changes in Inventories	-96.4	-275.3	-619.7	-271.7	-696.5	-494.3
Changes in Accounts Payable	1,059	736.8	735.1	598.6	-138.4	866.1
Changes in Unearned Revenue	30.2	-51.7	227.8	37.9	32.4	-120.2
Changes in Other Operating Activities	-394.4	-375.3	-407.5	-120.1	-148.6	-240.7
Operating Cash Flow	5,013	4,979	4,421	4,594	5,015	7,081
Operating Cash Flow Growth	26.80%	12.63%	-3.78%	-8.39%	-29.18%	170.47%
Capital Expenditures	-899.7	-898.4	-755.9	-718.6	-590.1	-551.9
Sale of Property, Plant & Equipment	-	-	20.1	-	-	-
Purchases of Intangible Assets	-322	-315.3	-125.7	-207.8	-1,027	-
Purchases of Investments	-11,175	-10,958	-16,617	-11,646	-7,488	-7,048
Proceeds from Sale of Investments	10,694	11,546	15,027	9,442	5,551	2,215
Payments for Business Acquisitions	-3.3	-3.3	-16.5	-54.9	-230.3	-
Investing Cash Flow	-1,706	-629.1	-2,468	-3,185	-3,785	-5,385
Issuance of Common Stock	738.4	635.9	1,465	1,146	1,520	1,672
Repurchase of Common Stock	-3,793	-3,971	-3,632	-2,936	-2,529	-2,678
Net Common Stock Issued (Repurchased)	-3,054	-3,335	-2,167	-1,790	-1,009	-1,006
Common Dividends Paid	-374.3	-370.3	-	-	-	-
Other Financing Activities	-	-10.3	-33.4	-	-	-
Financing Cash Flow	-3,428	-3,715	-2,201	-1,790	-1,009	-1,006
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-1.2	0.3	-0.7	-0.4	-	-
Net Cash Flow	-122.4	634.7	-248.8	-381.6	221.3	690.8
Free Cash Flow	4,113	4,081	3,665	3,875	4,425	6,529
Free Cash Flow Growth	0.80%	11.35%	-5.44%	-12.42%	-32.23%	225.90%
FCF Margin	27.57%	28.45%	25.80%	29.54%	36.35%	40.63%
Free Cash Flow Per Share	38.17	37.57	31.84	34.08	38.98	58.19
Levered Free Cash Flow	4,662	4,185	4,075	3,901	3,139	7,821
Unlevered Free Cash Flow	3,351	2,761	3,347	3,757	3,032	7,492

SEC Filings: 10-K · 10-Q